Medicinal mushroom Phellinus linteus as an alternative cancer therapy (Review)
- Daniel Sliva
- Corresponding author:
- Daniel Silva [ firstname.lastname@example.org ]
Published online on: Saturday, May 1, 2010
- Pages: 407-411 DOI: 10.3892/etm_00000063
Copyright: © Sliva et al. This is an open access article distributed under the terms of a Creative Commons Attribution License.
The anticancer activity of isolated compounds
The anticancer activity of P. linteus extracts
The popularity of complementary and alternative medicine (CAM) is steadily increasing among cancer patients, and CAM represents one of the fastest growing treatment modalities in the US (1). The most commonly used CAM includes acupuncture, mind-body approaches and dietary supplements. Specifically, among cancer patients, the use of CAM ranges between 30 and 75% worldwide and includes dietary approaches, herbal and other biologically based treatments (2). For example, herbal therapies are used by more than 12% of the US population each year, resulting in annual out-of-pocket expenses above $5 billion (3). In spite of the popularity of alternative cancer treatments with nutritional/dietary supplements among patients, sometimes based on the anecdotic evidence, CAM therapies are in many cases labeled as ‘pseudoscience’ (4). Therefore, rigorous scientific testing and safety evaluation of dietary supplements must be performed, after which clinicians can recommend the use of a particular dietary supplement (5).
Some of the popular, widely used dietary supplements are based on dried mushrooms or mushroom extracts. Notably, three recent epidemiological studies from Asia demonstrated an inverse correlation between mushroom intake and gastric, gastrointestinal and breast cancer, respectively (6–8). The anticancer activities of mushrooms were usually associated with the stimulation of the immune system by polysaccharides, predominantly β-glucans (9). On the other hand, mushrooms contain minerals, vitamins (e.g., thiamin, riboflavin, ascorbic acid and vitamin D), amino acids and other organic compounds (10).
Medicinal mushroom Phellinus linteus (Berk. et Curt.) Aoshima (‘meshimakobu’ in Japanese) has been used in traditional Oriental medicine in Japan, China and Korea (11). The orange/yellow-colored mushroom P. linteus (PL) is a perennial fungus, which is selectively parasitic on the mulberry tree (Morus) and belongs to Hymenochaetaceae basidiomycetes which consists of 220 known species of Phellinus mainly growing in tropical areas (12). More than 40 years ago, an original study in Japan demonstrated that PL has the strongest antitumor effects compared to other mushrooms (13). As previously reported, PL also demonstrates immunomodulatory, anti-inflammatory, anti-allergic, anti-angiogenic and anti-oxidant effects (14–18). These biological effects were found to be associated with isolated polysaccharides, proteoglycans and other organic compounds such as hispolon, caffeic acid, davallialactone, interfungins A and inoscavin A (17,19–22). Therefore, isolated compounds or complex extracts from PL demonstrate specific inhibition of signaling pathways in a variety of cancer cells.
The anticancer activity of isolated compounds
Polysaccharides isolated from P. linteus (PLP) significantly prolonged the survival of mice with implanted B16F10 melanoma cells. Moreover, PLP inhibited tumor growth and reduced the frequency of pulmonary metastasis. Notably, PLP was not directly toxic to cancer cells and its mechanism has been suggested to be through the stimulation of the immune response. Therefore, PLP has been recommended to patients as a natural immunotherapeutic agent without toxicity (23). The immunomodulatory effects of acid polysaccharide isolated from P. linteus (APPL) have been correlated with the increased production of nitric oxide (NO) and tumoricidal activity in murine peritoneal macrophages (24). In addition, genistein and staurosporine blocked NO production and tumoricidal activity in response to APPL in macrophages, suggesting that APPL activates protein tyrosine kinase (PTK) and/or protein kinase C (PKC) signaling in macrophages (24). In another study, APPL markedly suppressed the metastasis of melanoma cells in mice through the direct inhibition of cell adhesion and invasion (25). Nevertheless, APPL did not affect cell growth, suggesting that the antimetastatic properties of APPL are mediated through immunomodulation and by the direct inhibition of cell adhesion (25).
Although an oral application of the protein-glucan complex (PGC) isolated from P. linteus mycelia, consisting of 39.3% polysaccharides and 49.4% protein, suppressed the growth of S-180 sarcomas in mice, the mechanism of PGC activity was not determined (15). The polysaccharide-protein complex (PPC) extracted from P. linteus demonstrated immunomodulatory effects through the stimulation of the proliferation of B-cells in murine splenocytes and the induction of production of interleukin (IL)-1β, IL-6 and tumor necrosis factor-α (TNF-α) in peritoneal macrophages (26). Moreover, PPC up-regulated the macrophage-mediated tumoricidal activity by the secretion of NO and enhanced the natural killer (NK) cell cytotoxicity (26). On the other hand, protein-bound polysaccharide (PBP) isolated from P. linteus demonstrated a direct effect on cancer cells (27). Thus, PBP suppressed the proliferation and colony formation of SW480 human colon cancer cells. The inhibition of cell growth by PBP was mediated by the cell cycle arrest at G2/M phase and was associated with the down-regulation of expression of cell cycle regulatory protein cyclin B1 (27). Moreover, PBP induced the apoptosis of colon cancer cells, and this effect was associated with a decrease in Bcl-2 and an increase in the release of cytochrome c (27).
In addition to the anticancer activities of polysaccharides and their complexes (Table I), isolated low molecular weight compounds have exhibited specific effects on a variety of cancer cells. Hispolon isolated from P. linteus demonstrated a dose-dependent inhibition of human epidermoid KB cell proliferation (21). Furthermore, hispolon-induced apoptosis of KB cells was associated with the characteristic DNA laddering and with an increased amount of cells arrested in the sub-G1 phase of the cell cycle. These apoptotic events were accompanied by the collapse of mitochondrial membrane potential, the release of cytochrome c and the activation of caspase-3, suggesting that hispolon specifically induced the cell death of epidermoid cells through a mitochondria-mediated apoptotic pathway (21). As recently demonstrated, hispolon inhibited the proliferation and induced the apoptosis of breast and bladder cancer cells, independently of the tumor suppressor p53 status in these cells (28). The inhibition of cell growth was mediated by cell cycle arrest at the G2/M phase through the up-regulation of expression of cyclin-dependent kinase inhibitor p21, whereas apoptosis was linked to the ERK1/2-dependent induction of caspase-7 and PARP in breast and bladder cancer cells (28). Notably, hispolon down-regulated the expression of the MDM2 proto-oncogene through ERK1/2-mediated MDM2 ubiquitination suggesting the use of hispolon for cancer treatment (28). Recently, isolated phellifuropyranone A and meshimakobnol A and B demonstrated antiproliferative activity against mouse melanoma and human lung cancer cells in vitro, respectively (29), although the molecular mechanism responsible for their activity was not addressed (29).
The anticancer activity of P. linteus extracts
As mentioned above, various biologically active compounds demonstrating immunomodulatory or direct anticancer activities were isolated from P. linteus. However, mushrooms in traditional Oriental medicine or in the form of dietary supplements are usually used in the form of dried mushrooms or mushroom extracts. Therefore, a variety of studies have evaluated extracts from P. linteus for their biological activity (Fig. 1). The anticarcinogenic/chemopreventive potentials of extracts from cultured broth and mycelia of P. linteus (PL I and PL II) were suggested through the induction of the phase II enzyme, glutathione S-transferase (30). Mycelium extract from P. linteus (MEPL) inhibited the proliferation and induced the apoptosis of neuroblastoma SK-N-MC cells, as demonstrated by chromatin condensation and an increased amount of cells in the sub-G1 phase (31). These effects were associated with the induction of cyclin-dependent kinase inhibitor p21 the pro-apoptotic Bax protein. Moreover, MEPL stimulated caspase-3 activity and induced the proteolytic cleavage of specific target proteins such as PARP and β-catenin (31). In another study, combination treatment with low doses of P. linteus extract (PL) with the anticancer drug doxorubicin synergistically induced apoptosis in prostate cancer LNCaP cells through the activation of caspase-3 and -8 (32). Therefore, the combination of PL with other chemotherapeutic drugs reduces some of the side effects of these drugs by the use of lower doses in the combination treatment with PL. Moreover, PL specifically induced apoptosis in androgen receptor (AR)-positive prostate cancer LNCaP cells through the activation of caspase-2, whereas the induction of apoptosis in AR-negative prostate cancer PC-3 cells was caspase-2 independent; this suggested that PL activates AR-dependent and AR-independent apoptotic pathways (33). In addition, a low dose of PL induced cell cycle arrest at the G1 phase through the down-regulation of expression of cyclin-dependent kinases CDK-2, -4 and -6, whereas a high dose of PL induced apoptosis of lung cancer cells (34). An aqueous extract of Cambodian P. linteus (CPL) inhibited the adhesion to gelatin and the invasion of invasive melanoma B16BL6 cells as well as B16BL6-induced platelet aggregation (11). Moreover, CPL suppressed the pulmonary metastatic colonies in C57BL/6 mice intravenously injected with B16BL6 cells. This effect was associated with the down-regulation of expression of urokinase type plasminogen activator (uPA), suggesting that CPL may inhibit metastasis via regulation of uPA associated with tumor cell-induced platelet aggregation (11).
We recently demonstrated that PL inhibited proliferation and colony formation of highly invasive human breast cancer MDA-MB-231 cells (35). This effect was mediated by cell cycle arrest at the S phase through the up-regulation of expression of cyclin-dependent kinase inhibitor p27. PL also suppressed invasive behavior of MDA-MB-231 cells by the inhibition of cell adhesion, cell migration and cell invasion through the suppression of secretion of uPA (35). Moreover, PL significantly inhibited capillary morphogenesis of human aortic endothelial cells through the down-regulation of secretion of vascular endothelial growth factor from MDA-MB-231 cells. Thus, the inhibition of angiogenesis by PL was mediated by the suppression of the serine-threonine kinase AKT in breast cancer cells (35). Finally, extracts from P. linteus mycelia (PL-1 and PL-2) suppressed the activation of the aryl hydrocarbon receptor (AhR), the receptor activated by environmental pollutants and halogenated and polycyclic hydrocarbons, resulting in AhR-dependent gene expression (36). PL-1 also suppressed AhR-dependent gene expression triggered by cigarette smoke, suggesting the use of P. linteous for prevention of pathologies associated with aberrant activation of AhR, including smoking-associated diseases (36). In summary, a variety of P. linteus extracts demonstrated inhibitory activity against signaling pathways leading to the development and progression of cancer. Although some of these extracts were only partially characterized, these studies are important, since they reflect the use of extracts in traditional Oriental medicine.
Although three epidemiological studies have suggested that mushrooms may protect against cancer, the use of P. linteus was not addressed in these studies (6–8). In addition to the non-scientific anecdotic evidence, some sparse case reports have demonstrated the therapeutic effects of P. linteus extracts in patients. One case report from Japan described a positive response to P. linteus extract intake in a hormone refractory prostate cancer patient with rapidly progressive bone metastasis (37). Another case report from Korea described spontaneous regression of hepatocellular carcinoma (HCC) and metastatic frontal bone mass in a 65-year-old man after radiation therapy and ingestion of P. linteus for 18 months (38). Finally, HCC with multiple lung metastases completely regressed after 6 months in a 79-year-old man who independently ingested an extract from P. linteus mycelium for 1 month without any other therapy (39).
The therapeutic potential of isolated compounds or extracts from the medicinal mushroom P. linteus has been clearly demonstrated in rigorous scientific studies. In addition, the therapeutic effects of P. linteus extract were independently described in case reports. Collectively, these studies justify the use of dietary supplements containing P. linteus extract for the alternative treatment of cancer. One such dietary supplement is Breast-Mate®, whose major component is an extract from P. linteus which has exhibited antiproliferative, anti-invasive and anti-angiogenic activities against highly invasive human breast cancer cells.